Source page: McKinsey & Company
Commentary
Recharging vaccine R&D
Pharmaceuticals & Medical Products | Life Sciences | COVID-19
June 5, 2024 – Despite advances in vaccine innovation to combat COVID-19, progress for other vaccine archetypes has been uneven, say senior partner Adam Sabow and colleagues. Excluding COVID-19 vaccines, the number of infectious disease vaccine programs plateaued. However, the response to the pandemic strengthened the vaccine business case and led to a 30 percent overall increase in candidates over the past five years. Stakeholders can consider five actions to harness the pandemic-driven momentum to accelerate innovation and tackle global health. Click through the interactive to see more.
Interactive
To read the article, see “Beyond the pandemic: The next chapter of innovation in vaccines,” May 16, 2024.
customizer here
Visual form
Vaccine R&D pipeline chart.
Layout / body structure
The sequence moves from uneven progress across vaccine archetypes to the post-COVID strengthening of the vaccine business case.
What is being compared
It compares COVID-19 vaccine innovation momentum with non-COVID infectious disease vaccine programs and broader candidate growth.
Measurement system
The measures include number of vaccine programs, candidate counts, and percent increase in candidates over time.
Visible structure inside the graphic
The visual highlights a plateau in non-COVID infectious disease vaccine programs while showing that pandemic response increased overall vaccine candidate momentum.
Main takeaway from the visual
COVID-19 accelerated vaccine innovation, but that momentum needs to be deliberately redirected to other vaccine archetypes and global health needs.
Key standout values or extremes
Excluding COVID-19 vaccines, infectious disease vaccine programs plateaued. Overall candidates increased 30 percent over the past five years.
Controls / sequence, when applicable
This is an chart; the reader clicks through vaccine pipeline and momentum views.
Companion media, when applicable
There is no separate companion audio or video; the chart is the full visual on this page.